Abstract 182P
Background
While DNA NGS can detect clinically actionable fusions in tumors, technical and biological limitations may lead to false negatives, preventing patients from receiving approved therapies associated with outcome benefit. RNA NGS is recommended by ESMO guidelines to maximize fusion detection but is not widely used clinically. In a large, real-world dataset, we quantify the benefit of RNA concurrent with DNA NGS for ALK fusion detection in NSCLC.
Methods
We retrospectively analyzed de-identified stage IIIB-C and IV NSCLC samples sequenced with the Tempus xT assay (DNA and whole-exome capture RNA NGS). ALK fusion prevalence was compared to public DNA-seq-based data from Dana Farber Cancer Institute (DFCI, N=4,497) and Memorial Sloan Kettering Cancer Center (MSKCC, N=5,317) with one-sided proportion tests. ALK fusions were limited to known oncogenic partners detectable by FISH or IHC (EML4, KIF5B, KLC1, and PICALM). Therapeutic adoption was analyzed in cases with ≥90 days of first-line medication data.
Results
Among 7,428 NSCLC patients, 2.9% had ALK fusions (n=217), with 83% (n=180) detected by both DNA and RNA, 15% (n=33) from RNA alone, and 2% (n=4) from DNA alone. ALK fusion prevalence in the Tempus Database was higher than the combined MSKCC and DFCI rate (2.4%, n=236/9,814, P=0.036). To investigate RNA vs DNA discordance, we examined exonic EML4-ALK breakpoint locations (n=32). Most cases had canonical breakpoints in RNA (n=26), where 18 had no DNA support in these breakpoints, suggesting complex ALK rearrangements in DNA. The remaining 8 had limited DNA support but were below the clinical threshold for reporting. Of those with medication data (n=7), 6 patients with EML4-ALK fusions detected by RNA alone received targeted therapy post-testing and 5 remained on therapy for ≥100 days.
Conclusions
This large, real-world dataset demonstrates that RNA NGS increases ALK fusion detection by 18% over DNA alone for patients with advanced NSCLC. This increase is likely to translate to a larger number of patients matched to and receiving targeted therapy. Consequently, RNA NGS should be considered for more widespread adoption in the clinic.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Tempus Labs.
Disclosure
W. Iams: Financial Interests, Personal, Advisory Board: Tempus, EMD Serono, Amgen, Sanofi, NovoCure, Genentech, AstraZeneca, Catalyst, Jazz Pharma, Elevation Oncology, Bristol Myers Squibb, Janssen, Takeda, Mirati, G1 Therapeutics; Financial Interests, Personal, Other, Funding: Tempus. R. Ben-Shachar: Financial Interests, Personal, Full or part-time Employment: Tempus Labs; Financial Interests, Personal, Stocks/Shares: Tempus Labs, Myriad Genetics. L. Gai: Financial Interests, Institutional, Full or part-time Employment: Tempus Labs Inc. K. Beauchamp: Financial Interests, Personal, Full or part-time Employment: Tempus Labs, Inc; Financial Interests, Personal, Stocks/Shares: Tempus Labs, Inc. N. Sharma: Financial Interests, Personal, Full or part-time Employment: Tempus labs; Financial Interests, Personal, Stocks/Shares: Tempus labs. S. Islam: Financial Interests, Personal, Full or part-time Employment: Tempus Labs; Financial Interests, Personal, Stocks/Shares: Tempus Labs. J. Guinney: Financial Interests, Institutional, Full or part-time Employment: Tempus Labs; Financial Interests, Institutional, Stocks/Shares: Tempus Labs. H. Nimeiri: Financial Interests, Personal, Full or part-time Employment: Tempus; Financial Interests, Personal, Stocks/Shares: Tempus, AbbVie. R.D. Gentzler: Financial Interests, Personal, Advisory Board: AstraZeneca, Takeda, Gilead, Janssen, Mirati, Daiichi Sankyo, Sanofi, Oncocyte, Jazz Pharmaceuticals; Financial Interests, Personal, Invited Speaker: Clinical Care Options, OncLive, Targeted Oncology, Society for Immunotherapy of Cancer (SITC); Financial Interests, Institutional, Local PI: Janssen, Mirati, Daiichi Sankyo, Bristol Myers Squibb, AstraZeneca, Jounce Therapeutics, Takeda, Bristol Myers Squibb, Merck, Chugai, Amgen; Financial Interests, Institutional, Research Grant: Pfizer; Financial Interests, Institutional, Coordinating PI: Mirati; Non-Financial Interests, Leadership Role: Hoosier Cancer Research Network; Non-Financial Interests, Principal Investigator: NCI ETCTN; Non-Financial Interests, Other, Member of Lung Cancer Scientific Review Committee: American Society of Clinical Oncology, Scientific Review Committee; Non-Financial Interests, Other, Committee Member: NCI Investigational Drug Steering Committee; Non-Financial Interests, Officer, Associate Editor: Journal of Thoracic Oncology, ASCO Meeting Abstracts; Non-Financial Interests, Personal, Other, Travel support for attending meetings for invited speaker: International Association for the Study of Lung Cancer (IASLC). E. Cohen: Financial Interests, Personal, Other, Consulting: Eisai, Merck, MSD, Nectin Tx, Pangea Therapeutics, Roche, Adagene, Astellas, Cidara, Genmab, Gilboa, iTeos, Eli Lilly, Novartis, Nykode, PCI Biotech, Replimune, Soteria, Viracta; Financial Interests, Personal, Other, DSMB: Kura; Financial Interests, Personal, Other, BOD: Akamis Bio; Financial Interests, Personal, Stocks/Shares: Kinnate Biophama, Primmune Therapeutics.
Resources from the same session
155P - Exploring the utility of serum anti-tNASP antibodies as a screening biomarker in prostate, pancreatic, and ovarian cancer
Presenter: Oleg Alekseev
Session: Poster session 01
156P - The association between fibrotic endotypes, determined by pre-treatment serum levels of collagen metabolites, and survival outcomes in patients with pancreatic cancer
Presenter: Rasmus Pedersen
Session: Poster session 01
157P - CLDN18 fusions rather than expression is a biomarker related to the efficacy of paclitaxel in patients with ovarian metastasis of gastric cancer
Presenter: Pengfei Yu
Session: Poster session 01
158P - In silico analysis of HER2 enriched subtype and a HER2 index based on transcriptomic data of breast cancer compared to gastric and uterine serous carcinomas
Presenter: Arturo Gonzalez-Vilanova
Session: Poster session 01
159P - Better performance of pan-claudin18 antibodies on claudin18.2 detection in gastric adenocarcinoma than claudin18.2 specific antibody
Presenter: Shujuan NI
Session: Poster session 01
161P - Biomarkers of neoadjuvant combinational therapy for locally advanced gastric or gastroesophageal junction adenocarcinoma
Presenter: Yue Wang
Session: Poster session 01
162P - MR imaging biomarkers profiles in patients with prostate cancer treated with androgen deprivation therapy
Presenter: Angel Luis Sanchez Iglesias
Session: Poster session 01
163P - Genomic alterations in circulating tumor DNA (ctDNA) and response to ABBV-400 treatment in patients with advanced solid tumors
Presenter: Jair Bar
Session: Poster session 01
164P - Early evaluation of effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer
Presenter: Astrid Kramer
Session: Poster session 01